23.01.2024 – 14:01
Oncodesign Services
Dijon, France and Leiden, Netherlands (ots/PRNewswire)
Oncodesign Services (ODS), a leading contract research organization specializing in drug discovery and preclinical services, announces its international expansion through the acquisition of ZoBio, a Dutch CRO and expert in biophysically based small molecule drug discovery.
With this acquisition, ODS strengthens and expands its small molecule expertise and capabilities to support its customers’ innovative programs from target validation to candidate selection.
ODS is known for its expertise in the preclinical evaluation of experimental therapies in major disease areas such as oncology and immune-mediated inflammation, as well as its expertise in medicinal chemistry, computational chemistry, DMPK, pharmaco-imaging and molecular radiotherapy. The company has succeeded in developing several drug candidates that have reached the clinical development phase in collaboration with its customers.
Founded more than 19 years ago, ZoBio has earned a reputation for scientific excellence and innovation in biophysically based drug discovery. With its world-class platform of protein science, biophysical and functional assays, structural biology, and a unique, broad, small molecule fragment library, ZoBio has helped its customers advance numerous compounds through clinical development.
ODS and ZoBio employ a total of around 280 people at the locations in Dijon and Les Ulis in France, Leiden in the Netherlands and in subsidiaries in Canada and the USA. The agreement lays the foundation for ODS’ goal to become the European leader in drug discovery, offering fully integrated drug discovery services and solutions, placing quality, scientific creativity, operational excellence and transparent customer relationships at the heart of its strategy and invested in innovative technologies.
Dr. Fabrice Viviani, CEO of ODS, said: “I am very grateful to my management team, namely Gilles Cadiou, Sébastien Simon and Stéphanie Belattar, as well as our investors Jean-François Felix and Maxence de Vienne from Elyan Partners, for contributing to this success .
We are very pleased to welcome ZoBio to the group and thereby strengthen our offering in the area of preclinical services for small molecule drug discovery from gene to IND with state-of-the-art competencies and technologies.
Oncodesign Services and ZoBio complement each other excellently and we are very pleased that Gregg Siegal, Rob Heetebrij and Jan Schultz have decided to work with us to identify new preclinical candidates for our customers in important disease areas and to benefit from the numerous commercial and operational synergies .”
Dr. Gregg Siegal, CEO of ZoBio, said: “We are excited about the prospect of combining our world-class fragment-based drug discovery platform with the expertise of Oncodesign Services. We looked at many ways to strategically expand our capabilities to cover a larger portion of the drug development pipeline, and ODS was by far the best solution. Now we look forward to strengthening Fabrice’s team and offering our customers the best of both companies.”
About Oncodesign Services (ODS):
Oncodesign Services (ODS) is a leading contract research organization (CRO) specializing in drug development and preclinical services. The company contributes to the development of innovative therapies in the areas of oncology, inflammatory and infectious diseases and has extensive competencies in medicinal chemistry, DMPK, pharmaco-imaging, bioanalytics as well as in vivo and in vitro pharmacology. Oncodesign Services has 230 employees in France and Canada.
Further information: www.oncodesign-services.com
About ZoBio:
ZoBio has built an industry-leading platform that provides our customers with a complete solution for fragment-based drug discovery. Our gene-to-lead capabilities include: protein production, biophysical and functional assays, structural biology (crystallography, NMR & cryoEM) and fragment-based medicinal chemistry. Our dedicated 46-person team is at your side with their expertise to solve your biggest challenges in drug discovery.
Further information: http://www.zobio.com
Contact: [email protected]
Logo – https://mma.prnewswire.com/media/2324606/Oncodesign_Services_Logo.jpg
View original content: https://www.prnewswire.com/news-releases/oncodesign-services-ein-fuhrendes-europaisches-auftragsinstitut-in-der-praklinischen-wirkstoffforschung-erwirbt-zobio-ein-auf-die-entdeckung-von-niedermolekularen-arzneimitteln-spezialisiertes-cro-302041780.html
Press contact:
Nathalie Dubois,
marketing manager,
Oncodesign Services +33 3 80 78 82 60
Original content from: Oncodesign Services, transmitted by news aktuell